You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,518,123


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,518,123
Title:Compositions and methods for treatment of cancer
Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
Inventor(s): June; Carl H. (Merion Station, PA), Levine; Bruce L. (Cherry Hill, NJ), Porter; David L. (Springfield, PA), Kalos; Michael D. (Philadelphia, PA), Milone; Michael C. (Cherry Hill, NJ)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:14/997,042
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,518,123
Patent Claims:1. A human T cell comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain comprising, from the amino to the carboxy terminus, a light chain variable region and a heavy chain variable region of SEQ ID NO:20, wherein the CAR further comprises a transmembrane domain, a 4-1BB costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cells is from a human having cancer.

2. The human T cell of claim 1, wherein said antigen binding fragment is a scFv.

3. The human T cell of claim 2, wherein the scFv comprises the amino acid sequence of SEQ ID NO:20.

4. The human T cell of claim 1, wherein the transmembrane domain is CD8.alpha. transmembrane domain.

5. The human T cell of claim 4, wherein the CD8.alpha. transmembrane domain comprises the amino acid sequence of SEQ ID NO: 22.

6. The human T cell of claim 1, wherein the CAR further comprises a hinge domain.

7. The human T cell of claim 6, wherein the hinge domain is a CD8.alpha. hinge domain.

8. The human T cell of claim 7, wherein the CD8.alpha. hinge domain comprises the amino acid sequence of SEQ ID NO:21.

9. The human T cell of claim 1, wherein the 4-1BB costimulatory signaling region comprises the amino acid sequence of SEQ ID NO:23.

10. The human T cell of claim 1, wherein the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO: 24.

11. The human T cell of claim 1, wherein the CD19 antigen binding domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 14.

12. The human T cell of claim 5, wherein the CD8.alpha. transmembrane domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 16.

13. The human T cell of claim 8, wherein the CD8.alpha. hinge domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 15.

14. The human T cell of claim 9, wherein the 4-1BB costimulatory signaling region is encoded by a nucleic acid sequence comprising SEQ ID NO: 17.

15. The human T cell of claim 10, wherein the CD3 zeta signaling domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 18.

16. The human T cell of claim 1, wherein the CAR comprises the amino acid sequence of SEQ ID NO:12.

17. The human T cell of claim 16, wherein the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:8.

18. The human T cell of claim 1, wherein the CAR further comprises a CD28 costimulatory signaling region.

19. The human T cell of claim 1, wherein the cancer is a hematological cancer.

20. The human T cell of claim 1, wherein the T cell comprises a vector that comprises the nucleic acid sequence.

21. The human T cell of claim 20, wherein the vector is a lentiviral vector.

22. The human T cell of claim 21, wherein the vector further comprises a promoter.

23. The human T cell of claim 22, wherein the promoter is an EF-1.alpha. promoter.

24. The human T cell of claim 1, wherein the cell is isolated from a blood sample obtained from a human before the human is treated with a modality selected from the group consisting of an antiviral agent, chemotherapy, radiation, an immunosuppressive agent and an antibody.

25. The human cell of claim 24, wherein the antibody is selected from the group consisting of anti-CD3 antibody, natalizumab and efalizumab.

26. The human cell of claim 24, wherein the immunosuppressive agent is selected from the group consisting of cyclosporin, azathioprine, methotrexate, mycophenolate, FK506, CAMPATH, cytoxan, fludarabine, cyclosporin, FK506, rapamycin, mycophenolic acid, a steroid, and FR901228.

Details for Patent 9,518,123

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 05/07/2001 ⤷  Try a Trial 2030-12-09
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 11/14/2014 ⤷  Try a Trial 2030-12-09
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 10/12/2004 ⤷  Try a Trial 2030-12-09
Genentech, Inc. RAPTIVA efalizumab Injection 125075 10/27/2003 ⤷  Try a Trial 2030-12-09
Biogen Inc. TYSABRI natalizumab Injection 125104 11/23/2004 ⤷  Try a Trial 2030-12-09
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.